The Yale Diabetes Endocrinology Research Center was established in the Spring of 1993 with the goal of promoting research in diabetes and related metabolic and endocrine disorders at the University. The Center brings together a multidisciplinary group of nearly 100 independent member scientists as well as professional supporting staff, new investigators and research trainees from the Departments of Internal Medicine, Pediatrics, Immunobiology, Biology, Cell Biology, Molecular Biophysics and Biochemistry, Genetics, Molecular and Cellular Physiology, Pharmacology, Surgery, Orthopedics, Neurosurgery, Neurology, Psychiatry, Dermatology, Obstetrics and Gynecology, Diagnostic Radiology and from the Schools of Public Health and Nursing. The scope of the research activities of the membership is very broad, ranging from basic molecular biology to whole body clinical physiology in diabetic patients. The members, however, share a common interest in research that is related to diabetes and metabolism or is fundamental to understanding its pathogenesis or for the development of: new treatment strategies. The design of the Yale DERC is aimed at developing an infrastructure that could serve as a catalyst to stimulate innovative research. The cornerstone of the Center is its seven Research Cores that provide funded basic and clinical investigators with the opportunity to more efficiently utilize resources and expand the scope of their research programs. The Clinical Metabolism Core facilitates metabolic research in patients, whereas the Molecular, Microarray, Transgenic, Animal Genetics, Animal Physiology and Cell Biology Cores that comprise the Animal Resource Program offer investigators the tools to create and test novel animal models starting from the molecule and ending with biological outcomes. The Administrative Core oversees the operation of the Center, its Pilot/Feasibility Project and Enrichment Programs, and helps to coordinate patientbased research in diabetes. The goals of the DERC are to: 1) stimulate multidisciplinary interactions, particularly between basic and clinical scientists; 2) efficiently organize time consuming and/or costly techniques through Core facilities to enhance the productivity of investigators conducting research in diabetes related areas; 3) promote new research programs through pilot feasibility projects; 4) enhance the quality of research training, and 5) create an institutional environment that amplifies and expands research efforts in diabetes or related metabolic and endocrine disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
3P30DK045735-15S1
Application #
7501710
Study Section
Special Emphasis Panel (ZDK1-GRB-7 (O1))
Program Officer
Abraham, Kristin M
Project Start
1993-01-01
Project End
2007-12-31
Budget Start
2007-01-01
Budget End
2007-12-31
Support Year
15
Fiscal Year
2007
Total Cost
$92,789
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Vatner, Daniel F; Goedeke, Leigh; Camporez, Joao-Paulo G et al. (2018) Angptl8 antisense oligonucleotide improves adipose lipid metabolism and prevents diet-induced NAFLD and hepatic insulin resistance in rodents. Diabetologia 61:1435-1446
Keene, Danya E; Guo, Monica; Murillo, Sascha (2018) ""That wasn't really a place to worry about diabetes"": Housing access and diabetes self-management among low-income adults. Soc Sci Med 197:71-77
Hwang, Janice Jin; Parikh, Lisa; Lacadie, Cheryl et al. (2018) Hypoglycemia unawareness in type 1 diabetes suppresses brain responses to hypoglycemia. J Clin Invest 128:1485-1495
Wang, Yongliang; Nasiri, Ali R; Damsky, William E et al. (2018) Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer. Cell Rep 24:47-55
RISE Consortium (2018) Impact of Insulin and Metformin Versus Metformin Alone on ?-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care 41:1717-1725
Tan, Qiyuan; Tai, Ningwen; Li, Yangyang et al. (2018) Activation-induced cytidine deaminase deficiency accelerates autoimmune diabetes in NOD mice. JCI Insight 3:
Madiraju, Anila K; Qiu, Yang; Perry, Rachel J et al. (2018) Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nat Med 24:1384-1394
Goldberg, Ira J; Reue, Karen; Abumrad, Nada A et al. (2018) Deciphering the Role of Lipid Droplets in Cardiovascular Disease: A Report From the 2017 National Heart, Lung, and Blood Institute Workshop. Circulation 138:305-315
Stamatouli, Angeliki M; Quandt, Zoe; Perdigoto, Ana Luisa et al. (2018) Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes 67:1471-1480
Li, Nina Xiaoyan; Brown, Stacey; Kowalski, Tim et al. (2018) GPR119 Agonism Increases Glucagon Secretion During Insulin-Induced Hypoglycemia. Diabetes 67:1401-1413

Showing the most recent 10 out of 620 publications